home / stock / pavm / pavm quote
Last: | $1.04 |
---|---|
Change Percent: | -1.98% |
Open: | $1.03 |
Close: | $1.04 |
High: | $1.05 |
Low: | $0.9846 |
Volume: | 26,050 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.04 | $1.03 | $1.04 | $1.05 | $0.9846 | 26,050 | 07-22-2024 |
$1.01 | $1.04 | $1.01 | $1.1316 | $0.9953 | 42,576 | 07-19-2024 |
$1.04 | $1.2 | $1.04 | $1.23 | $1.017 | 71,600 | 07-18-2024 |
$1.155 | $1.06 | $1.155 | $1.34 | $1.06 | 276,173 | 07-17-2024 |
$1.04 | $0.95 | $1.04 | $1.06 | $0.95 | 105,581 | 07-16-2024 |
$0.94 | $0.84 | $0.94 | $0.945 | $0.84 | 98,621 | 07-15-2024 |
$0.859 | $0.88 | $0.859 | $0.9497 | $0.831 | 132,812 | 07-12-2024 |
$0.85 | $0.79 | $0.85 | $0.8699 | $0.79 | 88,387 | 07-11-2024 |
$0.8099 | $0.8 | $0.8099 | $0.82 | $0.76 | 52,243 | 07-10-2024 |
$0.78 | $0.79 | $0.78 | $0.819 | $0.750001 | 47,860 | 07-09-2024 |
$0.7943 | $0.73 | $0.7943 | $0.83 | $0.7297 | 19,877 | 07-08-2024 |
$0.708 | $0.7201 | $0.708 | $0.7299 | $0.7 | 13,348 | 07-05-2024 |
$0.708 | $0.71 | $0.708 | $0.73 | $0.708 | 10,821 | 07-04-2024 |
$0.708 | $0.71 | $0.708 | $0.73 | $0.708 | 10,821 | 07-03-2024 |
$0.71 | $0.75 | $0.71 | $0.79 | $0.71 | 52,285 | 07-02-2024 |
$0.764 | $0.815 | $0.764 | $1.09 | $0.764 | 129,147 | 07-01-2024 |
$0.815 | $0.86 | $0.815 | $0.8675 | $0.761 | 22,772 | 06-28-2024 |
$0.7667 | $0.75 | $0.7667 | $0.848657 | $0.75 | 17,835 | 06-27-2024 |
$0.742 | $0.778 | $0.742 | $0.778 | $0.741 | 35,249 | 06-26-2024 |
$0.741 | $0.829 | $0.741 | $0.8499 | $0.5999 | 71,808 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute PR Newswire First patients enrolled on the Veris Cancer Care Platform NEW YORK , ...